"Histamine H2 Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood.
| Descriptor ID |
D006635
|
| MeSH Number(s) |
D27.505.519.625.375.425.425 D27.505.696.577.375.425.425
|
| Concept/Terms |
Histamine H2 Antagonists- Histamine H2 Antagonists
- Receptor Blockaders, H2
- Blockaders, Histamine H2 Receptor
- Histamine H2 Receptor Blockaders
- Histamine H2 Blockers
- Blockers, Histamine H2
- H2 Blockers, Histamine
- Receptor Antagonists, Histamine H2
- Histamine H2 Receptor Antagonists
- Antagonists, Histamine H2
- H2 Antagonists, Histamine
- H2 Receptor Blockaders
- Blockaders, H2 Receptor
- Antihistaminics, H2
- H2 Antihistaminics
|
Below are MeSH descriptors whose meaning is more general than "Histamine H2 Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Histamine H2 Antagonists".
This graph shows the total number of publications written about "Histamine H2 Antagonists" by people in this website by year, and whether "Histamine H2 Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2017 | 3 | 4 | 7 |
| 2018 | 5 | 1 | 6 |
| 2019 | 2 | 1 | 3 |
| 2020 | 3 | 0 | 3 |
| 2021 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Histamine H2 Antagonists" by people in Profiles.
-
Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients. Signal Transduct Target Ther. 2021 07 14; 6(1):267.
-
Famotidine and Hospitalized COVID-19 Patients: Are the Benefits True? Am J Gastroenterol. 2021 07 01; 116(7):1561.
-
Association Between Famotidine Use and Clinical Outcomes in Patients With COVID-19: Assessment of Available Evidence. Am J Gastroenterol. 2021 04; 116(4):848-849.
-
Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review. Drug Res (Stuttg). 2021 Jul; 71(6):295-301.
-
Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis. Mayo Clin Proc. 2021 05; 96(5):1365-1367.
-
In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis. Mayo Clin Proc. 2021 05; 96(5):1367-1368.
-
Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis. Dig Dis Sci. 2021 11; 66(11):3929-3937.
-
Famotidine and Mortality in Coronavirus Disease 2019. Gastroenterology. 2021 07; 161(1):361-362.
-
Famotidine and Coronavirus Disease 2019. Gastroenterology. 2021 07; 161(1):360-361.
-
Potential Biases in Studies of Acid-Suppressing Drugs and COVID-19 Infection. Gastroenterology. 2021 04; 160(5):1443-1446.